Ferring Pharmaceuticals Co., Ltd Nippon Chemiphar Co., Ltd. December 11,2018

TRANSFER OF MARKETING AUTHORIZATION FOR ORAL INTESTINAL CLEANSING AGENT PICOPREP® IN JAPAN

Ferring Pharmaceuticals Co., Ltd. (HQ: Minato-ku, Tokyo; CEO: Mark Noggle; hereinafter "Ferring") and Nippon Chemiphar Co., Ltd. (HQ: Chiyoda-ku, Tokyo; President & CEO: Kazushiro Yamaguchi; hereinafter "Chemiphar") announced today that Ferring will transfer the marketing authorization for oral intestinal cleansing agent PICOPREP® combination powder to Chemiphar based upon a contract between both companies.

Under this contract, after completing the necessary procedures at the MHLW, the transfer of the marketing authorization for PICOPREP® from Ferring to Chemiphar is scheduled to take place in February 2019. At the same timing, Chemiphar will start marketing and selling the product.

1. Applicable item

Product name	PICOPREP® combination powder
Indication for use	Clean the bowel prior to endoscopy, to clean the bowel prior to
	surgery when judged clinically necessary.

2. About Ferring

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Ferring Pharmaceuticals Co., Ltd is a subsidiary in Japan since 2001. To learn more about Ferring or its products please visit www.ferring.com.

3. About Chemiphar

Nippon Chemiphar was established in 1950 and is engaged in ethical pharmaceuticals, diagnostics and healthcare-related products. The Company continues to expand its business through strategic growth in the areas of generic drugs, hyperuricemia and in-house drug discovery in Japan and overseas. Regarding drug discovery, the Company is focused on developing new breakthrough drugs which has enabled it to successfully discover a number of hopeful compounds in recent years.

For further information contact:

Public Relations Department, Nippon Chemiphar Co., Ltd.

E-mail: ir@chemiphar.co.jp